COVID-19 fulminant myocarditis: a case report
Open Access
- 8 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 4 (FI1), 1-6
- https://doi.org/10.1093/ehjcr/ytaa212
Abstract
Fulminant myocarditis is a catastrophic disease with high mortality and complications. A viral aetiology is frequent and the implication of SARS-CoV-2 is not yet known. A 38-year-old woman who recently arrived from Spain presented with palpitations that started suddenly 3 days prior to presentation and were associated with haemodynamic instability, without dyspnoea or chest pain. We found features of myopericarditis on the electrocardiogram and severe systolic dysfunction on the echocardiogram. The chest tomography showed findings which suggested COVID-19 infection, and PCR for SARS-CoV-2 was positive. The cardiac magnetic resonance image showed Lake Louise criteria for myocarditis. The patient was treated with immunomodulatory, steroid, and immunoglobulin therapy, with a favourable clinical response. The importance of this case lies in highlighting the severe cardiac involvement in a young patient, without previous risk factors, positive for COVID-19, and the favourable response to the medical treatment given.Keywords
Funding Information
- Universidad Libre
This publication has 15 references indexed in Scilit:
- Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulinEuropean Heart Journal, 2021
- Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)JAMA Cardiology, 2020
- A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysisProgress in Cardiovascular Diseases, 2020
- Recognition and Initial Management of Fulminant Myocarditis A Scientific Statement From the American Heart AssociationCirculation, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- A life support-based comprehensive treatment regimen dramatically lowers the in-hospital mortality of patients with fulminant myocarditis: a multiple center studyScience China Life Sciences, 2019
- SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARSEuropean Journal of Clinical Investigation, 2009